The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic merkel cell carcinoma (MCC) (CheckMate 358).
 
Shailender Bhatia
Stock and Other Ownership Interests - Moderna Therapeutics
Honoraria - Bristol-Myers Squibb; EMD Serono; EMD Serono; Genentech/Roche; Incyte; Sanofi/Regeneron; Sanofi/Regeneron
Consulting or Advisory Role - Bristol Myers Squibb; Bristol-Myers Squibb; EMD Serono; EMD Serono; Exicure; Genentech/Roche; Sanofi/Regeneron; Sanofi/Regeneron; Sanofi/Regeneron (Inst)
Research Funding - 4SC (Inst); Amphivena (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); Exicure (Inst); Incyte (Inst); Merck (Inst); NantWorks (Inst); Nektar (Inst); Novartis (Inst); Seven and Eight Biopharmaceuticals (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - NantWorks; Sanofi/Regeneron
 
Suzanne Louise Topalian
Stock and Other Ownership Interests - Atengen; DNAtrix (I); Dracen (I); Dragonfly Therapeutics; Enara Bio (I); ManaT Bio (I); RAPT Therapeutics (I); Tizona Therapeutics, Inc. (I); TRex Bio (I); Trieza Therapeutics (I); WindMIL (I)
Consulting or Advisory Role - Amgen (I); AstraZeneca/MedImmune (I); Bristol-Myers Squibb/Celgene (I); Compugen (I); Dracen (I); Dragonfly Therapeutics; Five Prime Therapeutics; Immunocore; Immunomic Therapeutics (I); Janssen Oncology (I); PATHAI; RAPT Therapeutics (I); Shattuck Labs (I); Tempest Therapeutics (I); Tizona Therapeutics, Inc. (I); WindMIL (I)
Research Funding - Bristol-Myers Squibb; Compugen (I); Enara Bio (I)
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb (I); Immunonomic Therapeutics (I); Intellectual property related to MSI as an immunotherapy biomarker. (Inst); WindMIL (I)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Dragonfly Therapeutics
 
William Howard Sharfman
Honoraria - Bristol-Myers Squibb; Merck; Regeneron
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Regeneron
Research Funding - AstraZeneca; Bristol-Myers Squibb; Genentech; Merck; Novartis
 
Tim Meyer
Consulting or Advisory Role - Bayer; Beigene; BTG; Eisai; Ipsen; MSD; Roche
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Christopher D. Lao
Consulting or Advisory Role - BMS
Research Funding - Bristol-Myers Squibb; Genentech; Novartis; Oncosec
 
Lorena Fariñas-Madrid
Consulting or Advisory Role - GlaxoSmithKline
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; MSD Oncology
Travel, Accommodations, Expenses - AstraZeneca Spain; GlaxoSmithKline; MSD Oncology
 
Lot A. Devriese
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst)
 
Raid Aljumaily
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Regeneron
Research Funding - Abbvie (Inst); Alliance Foundation Trials (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Baxalta (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Huntsman Cancer Institute (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Syneos Health (Inst); Tesaro (Inst)
 
Robert L. Ferris
Stock and Other Ownership Interests - Novasenta
Consulting or Advisory Role - Achilles Therapeutics; Adagene; Aduro Biotech; Bicara Therapeutics; Bristol-Myers Squibb; Cantenion; Coherus Biosciences; Eterna Therapeutics; Everest Clinical Research; F. Hoffmann LaRoche; Genocea Biosciences; Hookipa Pharma; Instil Bio; Kowa Research Institute; Lifescience Dynamics; Macrogenics; MeiraGTx; Merck; Mirati Therapeutics; Mirror Biologics; Nanobiotix; Novartis; Novasenta; Numab; OncoCyte; Pfizer; PPD; Rakuten Medical; Sanofi; Seagen; SIRPant Immunotherapeutics; VIR Biotechnology; Zymeworks; Zymeworks
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Novasenta; Tesaro
 
Yoshitaka Honma
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Eisai; Janssen; Rakuten Aspyrian
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Research Funding - Adlai Nortye; Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma; GlaxoSmithKline; Janssen; Maruho; Merck Serono; MSD; Novartis; Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical
 
Tariq Aziz Khan
Employment - Bristol-Myers Squibb/Celgene
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene
 
Anjaiah Srirangam
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Charlie Garnett-Benson
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Michelle Lee
Employment - Bristol-Myers Squibb; Syneos Health
 
Paul Nghiem
Honoraria - EMD Serono; Instil Bio; Rain Therapeutics
Consulting or Advisory Role - Almirall